Meeting
2022 ASCO Genitourinary Cancers Symposium
Mixed methods assessment of providers’ needs in the management of advanced renal cell carcinoma.
Authors
Matthew T Campbell
The University of Texas MD Anderson Cancer Center, Houston, TX
Matthew T Campbell , Patrice Lazure , Monica Augustyniak , Edgar A. Jaimes , Mehmet Asim Bilen , Emily Lemke , Ginny Jacobs , Pamela McFadden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 313)
DOI
10.1200/JCO.2022.40.6_suppl.313
Abstract #
313
Poster Bd #
E3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Predicting perioperative complications for partial versus radical nephrectomy in T1b-T2 renal cell carcinoma.
First Author: Yash Shah
Poster
2024 ASCO Genitourinary Cancers Symposium
The feasibility of an educational and monitoring smartphone application for patients with advanced renal cell carcinoma undergoing combination immunotherapy.
First Author: Gabriel Roman Souza
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
First Author: Pratik Rane
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan